Illumina (ILMN) Countersues IBS, Qiagen (QGEN) in Patent Suit
Tweet Send to a FriendGet Alerts ILMN Hot Sheet
Trade ILMN Now!
Illumina, Inc. (Nasdaq: ILMN) has sought leave to file counterclaims against Intelligent Bio-Systems, Inc. (IBS) and Qiagen NV (Nasdaq: QGEN), which recently acquired IBS, in response to the patent lawsuit brought by Columbia University and IBS on March 26, 2012 in U.S. District Court in Wilmington, Delaware. In its counterclaims, Illumina has sued IBS and Qiagen for infringement of three Illumina patents, entitled “Labelled Nucleotides.” These three patents (U.S. Patent Nos. 7,057,026; 7,785,796; and 8,158,346, all expiring in December 2022), are applicable to the sequencing by synthesis technology being used in the IBS Max-Seq and MINI-20 DNA Sequencers. Illumina is seeking all available remedies, including injunctive relief. With respect to the claims brought by Columbia and IBS, Illumina has denied all of Columbia’s and IBS’s allegations of patent infringement, and has asserted that Columbia’s patents are invalid.
Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. Illumina owns or has exclusive licenses to more than 250 patents granted in the U.S., and many additional patents granted worldwide, to protect its massive investments in research and development and resulting technological breakthroughs.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. Illumina owns or has exclusive licenses to more than 250 patents granted in the U.S., and many additional patents granted worldwide, to protect its massive investments in research and development and resulting technological breakthroughs.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Hess (HES), Elliott to End Proxy Contest; Three Elliott Nominees Will be Added
- Novo Nordisk (NVO) Reports Positive Results from Paradigm 2
- U.S. SEC Appoints Lona Nallengara as Chief of Staff; Keith Higgins as Corp. Finance Director
Create E-mail Alert Related Categories
Corporate News, Litigation
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
